Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today that its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, will host a conference call to discuss the Company's quarterly results for the period ending March 31, 2008. The call will be held Wednesday, May 14, 2008 at 8:30 a.m. EDT.

The Company invites all interested parties to participate. The call will be web cast and accessible live through the following URL: http://ir.javelinpharmaceuticals.com/events.cfm. The call will be archived on the Company's website www.javelinpharmaceuticals.com.

CONFERENCE CALL ALERT

Javelin Pharmaceuticals, Inc. Q1 2008 Earnings Call

Date: May 14, 2008

Time: 8:30 a.m. E.D.T.

Please dial: (877) 604-9667 or International (719) 325-4895

About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in US Phase 3 clinical development. One of these US Phase 3 drug candidates, Dyloject™, has received Marketing Authorization Application (MAA) approval and favorable pricing in the UK, where it is now being sold. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com.

Forward Looking Statement:

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.